<p>DAFNA Capital Management LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免费报告) 的持股比例提高了 9.3%。该基金在此期间购买了额外的 19,000 股后，持有该医疗设备公司 223,208 股股票。Tandem Diabetes Care 占 DAFNA Capital Management LLC 持有资产的约 2.0%，使其成为该基金第 16 大持股。截至最近向证券交易委员会（SEC）提交的文件，DAFNA Capital Management LLC 持有的 Tandem Diabetes Care 的股份约占 0.34%，价值 8,040,000 美元。</p>
<p>获取 <strong>Tandem Diabetes Care</strong> 警报：</p>
<p>其他一些对冲基金最近也增加或减少了对该股票的持股。Hood River Capital Management LLC 在第四季度收购了价值约 46,035,000 美元的 Tandem Diabetes Care 新股份。Brown Advisory Inc. 在第四季度购买了价值 32,889,000 美元的 Tandem Diabetes Care 新股份。Park West Asset Management LLC 在第四季度将其在 Tandem Diabetes Care 的持股比例提高了 49.5%。Park West Asset Management LLC 现在持有 1,600,000 股该医疗设备公司的股票，价值 57,632,000 美元，此前在上个季度又购买了 530,000 股。Baillie Gifford &amp; Co. 在第四季度将其在 Tandem Diabetes Care 的持股比例提高了 235.7%。Baillie Gifford &amp; Co. 现在持有 746,109 股该医疗设备公司的股票，价值 26,875,000 美元，此前在上个季度又购买了 523,843 股。最后，ArrowMark Colorado Holdings LLC 在第四季度将其在 Tandem Diabetes Care 的持股比例提高了 14.1%。ArrowMark Colorado Holdings LLC 现在持有 2,723,715 股该医疗设备公司的股票，价值 98,108,000 美元，此前在上个季度又购买了 337,026 股。</p>
<h2>内部活动</h2>
<p>在其他 Tandem Diabetes Care 的新闻中，首席运营官 Jean-Claude Kyrillos 于 3 月 7 日星期五收购了 10,538 股公司的股票。该股票的平均购买价格为每股 18.12 美元，总交易额为 190,948.56 美元。收购后，首席运营官现在持有 10,538 股公司股票，价值约 190,948.56 美元。此次交易使其持股比例增加了 ∞。该购买在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有公司股票的 1.90%。</p>
<h2>Tandem Diabetes Care 股票上涨 4.4%</h2>
<p>TNDM 股票在周四开盘价为 22.26 美元。该股票的市值为 14.8 亿美元，市盈率为 -11.53，贝塔值为 1.47。公司快速比率为 2.32，流动比率为 2.90，债务与股本比率为 1.29。该公司有 50 日移动平均线为 18.55 美元，200 日移动平均线为 28.34 美元。Tandem Diabetes Care, Inc. 的 52 周低点为 15.75 美元，52 周高点为 53.69 美元。</p>
<p>Tandem Diabetes Care (NASDAQ:TNDM - 获取免费报告) 最近于 4 月 30 日星期三公布了季度财报。该医疗设备公司报告的每股收益（EPS）为 -0.67 美元，低于分析师一致预期的 -0.60 美元，差额为 -0.07 美元。Tandem Diabetes Care 的净利润率为 -14.84%，股本回报率为 -44.19%。该公司在本季度的收入为 2.3442 亿美元，而分析师预期为 2.2019 亿美元。在去年同期，该公司每股收益为 -0.65 美元。与去年同期相比，该公司的收入增长了 22.3%。卖方分析师预测，Tandem Diabetes Care, Inc. 本年度将发布 -1.68 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>一些券商最近对 TNDM 发布了报告。花旗集团将 Tandem Diabetes Care 的股票评级从 &#34;买入&#34; 下调至 &#34;中性&#34;，并在 3 月 4 日星期二的研究报告中将其目标价从 35.00 美元下调至 24.00 美元。瑞穗证券在 4 月 10 日星期四的研究报告中开始对 Tandem Diabetes Care 进行覆盖。他们给予了 &#34;中性&#34; 评级，并设定了 20.00 美元的目标价。Piper Sandler 在 5 月 1 日星期四的报告中将 Tandem Diabetes Care 的目标价从 36.00 美元下调至 30.00 美元，并对该股票给予了 &#34;增持&#34; 评级。桑福德·C·伯恩斯坦在 2 月 28 日星期五的报告中将 Tandem Diabetes Care 的股票评级从 &#34;跑赢大盘&#34; 下调至 &#34;市场表现&#34;，并将其目标价从 35.00 美元下调至 25.00 美元。最后，摩根士丹利在 3 月 5 日星期三的报告中将 Tandem Diabetes Care 的股票评级从 &#34;增持&#34; 下调至 &#34;持平&#34;，并将其目标价从 45.00 美元下调至 22.00 美元。八位分析师对该股票给予了持有评级，九位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 39.81 美元。</p>
<p><strong>阅读我们关于 Tandem Diabetes Care 的最新股票报告</strong></p>
<h2>关于 Tandem Diabetes Care</h2>
<p>（免费报告）</p>
<p>Tandem Diabetes Care, Inc. 是一家医疗设备公司，设计、开发并商业化针对美国及国际糖尿病患者的技术解决方案。该公司的旗舰产品是 t:slim X2 胰岛素输送系统，这是一个用于管理胰岛素输送并在泵的主屏幕上直接显示连续血糖监测传感器信息的泵平台；以及 Tandem Mobi 胰岛素泵，这是一个自动胰岛素输送系统。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Tandem Diabetes Care</li>
<li>理解看涨期权交易量对成功的期权交易至关重要</li>
<li>DexCom 股票：盈利超预期和新市场准入推动牛市前景</li>
<li>投资中的下调意味着什么？</li>
<li>优步的财报为股票和更广泛的经济提供线索</li>
<li>ETF 会支付股息吗？你需要知道的事项</li>
<li>机构错过了反弹：资金流向何处</li>
</ul>
<p><strong>想看看其他对 TNDM 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Tandem Diabetes Care 吗？</h2>
<p>在考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Tandem Diabetes Care 并不在名单上。</p>
<p>虽然 Tandem Diabetes Care 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TNDM

<p>DAFNA Capital Management LLC 在第四季度将其在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM) 的持股增加了 9.3%，额外购买了 19,000 股，总持股量达到 223,208 股。这项投资约占 DAFNA 持有资产的 2.0%，价值约为 804 万美元。其他对冲基金也调整了在 Tandem 的持股。该股票最近上涨了 4.4%，开盘价为 22.26 美元，市值为 14.8 亿美元。尽管每股收益未达到预期，Tandem 报告的收入同比增长了 22.3%</p>

<p>DAFNA Capital Management LLC boosted its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,208 shares of the medical device company's stock after purchasing an additional 19,000 shares during the period. Tandem Diabetes Care comprises about 2.0% of DAFNA Capital Management LLC's holdings, making the stock its 16th largest holding. DAFNA Capital Management LLC owned about 0.34% of Tandem Diabetes Care worth $8,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>DAFNA Capital Management LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免费报告) 的持股比例提高了 9.3%。该基金在此期间购买了额外的 19,000 股后，持有该医疗设备公司 223,208 股股票。Tandem Diabetes Care 占 DAFNA Capital Management LLC 持有资产的约 2.0%，使其成为该基金第 16 大持股。截至最近向证券交易委员会（SEC）提交的文件，DAFNA Capital Management LLC 持有的 Tandem Diabetes Care 的股份约占 0.34%，价值 8,040,000 美元。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tandem Diabetes Care</strong> 警报：</p>
</div><p>A number of other hedge funds have also recently added to or reduced their stakes in the stock. Hood River Capital Management LLC acquired a new stake in Tandem Diabetes Care in the fourth quarter valued at approximately $46,035,000. Brown Advisory Inc. bought a new position in shares of Tandem Diabetes Care in the fourth quarter worth $32,889,000. Park West Asset Management LLC grew its stake in Tandem Diabetes Care by 49.5% in the 4th quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock worth $57,632,000 after buying an additional 530,000 shares in the last quarter. Baillie Gifford &amp; Co. lifted its stake in Tandem Diabetes Care by 235.7% in the fourth quarter. Baillie Gifford &amp; Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after purchasing an additional 523,843 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after purchasing an additional 337,026 shares during the last quarter.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也增加或减少了对该股票的持股。Hood River Capital Management LLC 在第四季度收购了价值约 46,035,000 美元的 Tandem Diabetes Care 新股份。Brown Advisory Inc. 在第四季度购买了价值 32,889,000 美元的 Tandem Diabetes Care 新股份。Park West Asset Management LLC 在第四季度将其在 Tandem Diabetes Care 的持股比例提高了 49.5%。Park West Asset Management LLC 现在持有 1,600,000 股该医疗设备公司的股票，价值 57,632,000 美元，此前在上个季度又购买了 530,000 股。Baillie Gifford &amp; Co. 在第四季度将其在 Tandem Diabetes Care 的持股比例提高了 235.7%。Baillie Gifford &amp; Co. 现在持有 746,109 股该医疗设备公司的股票，价值 26,875,000 美元，此前在上个季度又购买了 523,843 股。最后，ArrowMark Colorado Holdings LLC 在第四季度将其在 Tandem Diabetes Care 的持股比例提高了 14.1%。ArrowMark Colorado Holdings LLC 现在持有 2,723,715 股该医疗设备公司的股票，价值 98,108,000 美元，此前在上个季度又购买了 337,026 股。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction on Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Tandem Diabetes Care 的新闻中，首席运营官 Jean-Claude Kyrillos 于 3 月 7 日星期五收购了 10,538 股公司的股票。该股票的平均购买价格为每股 18.12 美元，总交易额为 190,948.56 美元。收购后，首席运营官现在持有 10,538 股公司股票，价值约 190,948.56 美元。此次交易使其持股比例增加了 ∞。该购买在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有公司股票的 1.90%。</p>
</div><h2>Tandem Diabetes Care Stock Up 4.4 %</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股票上涨 4.4%</h2>
</div><p>TNDM stock opened at $22.26 on Thursday. The stock has a market capitalization of $1.48 billion, a PE ratio of -11.53 and a beta of 1.47. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm has a 50 day moving average of $18.55 and a 200 day moving average of $28.34. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69.</p>
<div class="lb-trans"><p>TNDM 股票在周四开盘价为 22.26 美元。该股票的市值为 14.8 亿美元，市盈率为 -11.53，贝塔值为 1.47。公司快速比率为 2.32，流动比率为 2.90，债务与股本比率为 1.29。该公司有 50 日移动平均线为 18.55 美元，200 日移动平均线为 28.34 美元。Tandem Diabetes Care, Inc. 的 52 周低点为 15.75 美元，52 周高点为 53.69 美元。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period in the previous year, the firm posted ($0.65) earnings per share. The company's revenue was up 22.3% compared to the same quarter last year. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care (NASDAQ:TNDM - 获取免费报告) 最近于 4 月 30 日星期三公布了季度财报。该医疗设备公司报告的每股收益（EPS）为 -0.67 美元，低于分析师一致预期的 -0.60 美元，差额为 -0.07 美元。Tandem Diabetes Care 的净利润率为 -14.84%，股本回报率为 -44.19%。该公司在本季度的收入为 2.3442 亿美元，而分析师预期为 2.2019 亿美元。在去年同期，该公司每股收益为 -0.65 美元。与去年同期相比，该公司的收入增长了 22.3%。卖方分析师预测，Tandem Diabetes Care, Inc. 本年度将发布 -1.68 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages recently issued reports on TNDM. Citigroup cut shares of Tandem Diabetes Care from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Mizuho began coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a &#34;neutral&#34; rating and a $20.00 price objective for the company. Piper Sandler decreased their price target on Tandem Diabetes Care from $36.00 to $30.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, May 1st. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their price target for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Morgan Stanley downgraded shares of Tandem Diabetes Care from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and reduced their target price for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $39.81.</p>
<div class="lb-trans"><p>一些券商最近对 TNDM 发布了报告。花旗集团将 Tandem Diabetes Care 的股票评级从 &#34;买入&#34; 下调至 &#34;中性&#34;，并在 3 月 4 日星期二的研究报告中将其目标价从 35.00 美元下调至 24.00 美元。瑞穗证券在 4 月 10 日星期四的研究报告中开始对 Tandem Diabetes Care 进行覆盖。他们给予了 &#34;中性&#34; 评级，并设定了 20.00 美元的目标价。Piper Sandler 在 5 月 1 日星期四的报告中将 Tandem Diabetes Care 的目标价从 36.00 美元下调至 30.00 美元，并对该股票给予了 &#34;增持&#34; 评级。桑福德·C·伯恩斯坦在 2 月 28 日星期五的报告中将 Tandem Diabetes Care 的股票评级从 &#34;跑赢大盘&#34; 下调至 &#34;市场表现&#34;，并将其目标价从 35.00 美元下调至 25.00 美元。最后，摩根士丹利在 3 月 5 日星期三的报告中将 Tandem Diabetes Care 的股票评级从 &#34;增持&#34; 下调至 &#34;持平&#34;，并将其目标价从 45.00 美元下调至 22.00 美元。八位分析师对该股票给予了持有评级，九位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 39.81 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Tandem Diabetes Care 的最新股票报告</strong></p>
</div><h2>About Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>关于 Tandem Diabetes Care</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc. 是一家医疗设备公司，设计、开发并商业化针对美国及国际糖尿病患者的技术解决方案。该公司的旗舰产品是 t:slim X2 胰岛素输送系统，这是一个用于管理胰岛素输送并在泵的主屏幕上直接显示连续血糖监测传感器信息的泵平台；以及 Tandem Mobi 胰岛素泵，这是一个自动胰岛素输送系统。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Uber’s Earnings Offer Clues on the Stock and Broader Economy</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Institutions Skipped the Rally: Where the Money Went</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Tandem Diabetes Care</li>
<li>理解看涨期权交易量对成功的期权交易至关重要</li>
<li>DexCom 股票：盈利超预期和新市场准入推动牛市前景</li>
<li>投资中的下调意味着什么？</li>
<li>优步的财报为股票和更广泛的经济提供线索</li>
<li>ETF 会支付股息吗？你需要知道的事项</li>
<li>机构错过了反弹：资金流向何处</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNDM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 TNDM 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tandem Diabetes Care 吗？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Tandem Diabetes Care 并不在名单上。</p>
</div><p>While Tandem Diabetes Care currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tandem Diabetes Care 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

DAFNA 资本管理有限责任公司购入了 Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM）19,000 股股票